Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  O'Connor, Christopher M ^a   Fiuzat, Mona ^a   Carson, Peter E ^b   Anand, Inder S ^b   Plehn, Jonathan F ^c   Gottlieb, Stephen S ^d   Silver, Marc A ^e   Lindenfeld, JoAnn ^f   Miller, Alan B ^g   White, Michel ^h   Walsh, Ryan ^f   Nelson, Penny ^f   Medway, Allen ^f   Davis, Gordon ⁱ   Robertson, Alastair D ^f   Port, J David ^f,i   Carr, James ⁱ   Murphy, Guinevere A ⁱ   Lazzeroni, Laura C ^j   Abraham, William T ^k   Liggett, Stephen B ^l   Bristow, Michael R ^f,i   more..

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e ADVOCATE CHRIST MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

ⁱ ARCA Biopharma   (United States)

^j STANFORD UNIVERSITY   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BUCINDOLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCINE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXPLANT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-1;

EID: 84867393652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044324     Document Type: Article

References (23)

1. [No authors listed] (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353: 9-13.
2. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215-225.
3. [No authors listed] (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007.
4. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658.
5. The Beta Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659-1667.
6. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, et al. (2003) A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9: 354-363.
7. O'Connor CM, Fiuzat M, Caron MF, Deedwania P, Follmann D, et al. (2011) Influence of global region on outcomes in large heart failure β-blocker trials. J Am Coll Cardiol 58: 915-922.
8. Metra M, Bristow MR (2010) Beta-blocker therapy in chronic heart failure. In: Mann DL, ed. Heart Failure: A companion to Braunwald's Heart Disease.
9. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB, (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135-1142.
10. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al. (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9: 1300-1305.
11. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103: 11288-11293.
12. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, et al. (2010) An α2C-adrenergic receptor polymorphism alters the norepinephrine lowering effects and therapeutic response of the beta blocker bucindolol in chronic heart failure. Circ Heart Fail 3: 21-28.
13. Mason DA, Moore JD, Green SA, Liggett SB, (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274: 12670-12674.
14. Sandilands AJ, O'Shaughnessy KM, Brown MJ, (2003) Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 β1-adrenoceptors versus Gly389 β1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol 138: 386-392.
15. Hein L, Altman JD, Kobilka BK, (1999) Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402: 181-184.
16. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB, (2000) A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275: 23059-23064.
17. Evans WE, Relling MV, (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429: 464-468.
18. Sadee W, Dai Z, (2005) Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14 (2): R207-R214.
19. Hershberger RE, Wynn JR, Sundberg L, Bristow MR, (1990) Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharm 15: 959-967.
20. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, et al. (2004) Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial (BEST). Circulation 110: 1437-1442.
21. Woodcock J, Lesko LJ, (2009) Pharmacogenetics-tailoring treatment for the outliers. N Engl J Med 360: 811-813.
22. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, et al. (2003) An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5: 463-468.
23. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, et al. (2008) Lack of association between beta adrenergic receptor genotype and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol 52: 644-651.